QuickMIC proven 75% faster in sepsis diagnostics in a global multicenter study

21 Oct 2025

QuickMIC® – Ultra-rapid antibiotic susceptibility testing — QuickMIC^® – Ultra-rapid antibiotic susceptibility testing

Gradientech has announced a new scientific publication confirming the QuickMIC^® system to deliver accurate antibiotic susceptibility testing (AST) results up to 75% faster than current gold-standards automated solutions, enabling faster treatment decision for sepsis and blood stream infections. The clinical data is published in the high-ranked European Journal of Clinical Microbiology & Infectious Diseases¹.

Conducted across four leading hospitals in Europe and the United States, the international multicenter study demonstrates that the QuickMIC ultra-rapid AST system significantly reduces the time needed to deliver actionable results for bloodstream infections, while maintaining high accuracy.

The study evaluated 155 patient samples across 10 species of Gram-negative bacteria, comparing the QuickMIC system to three widely used automated AST platforms. The QuickMIC system demonstrated an essential and categorical agreement of over 95% with the routine systems – a strong indicator of test accuracy.

More strikingly, the average time-to-result (TTR) with QuickMIC was just 3 hours and 4 minutes, compared to 9–19 hours for standard of care systems. This translates to a 53–75% reduction in overall turnaround time (TAT, the total time of the diagnostic workflow from blood culture positivity) – with QuickMIC delivering actionable results in 10–11.5 hours, versus 22–45 hours for current methods.

“This international multicenter study is another brick in building solid proof of the clinical value that QuickMIC brings. By reducing turnaround time by up to 75%, it addresses a critical need in sepsis care – delivering rapid, reliable results when early, targeted therapy can save lives,” said Sara Thorslund, co-founder and CEO at Gradientech.

QuickMIC^® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

References

1. Multicenter evaluation of the QuickMIC^® rapid AST system in clinical practice: impact on turnaround time compared to routine AST systems. European Journal of Clinical Microbiology & Infectious Diseases. Published: 13 October 2025. https://doi.org/10.1007/s10096-025-05298-z